Nejla Israel, MD
Family Medicine · Oak Park, MINPI 1821045311
Payments from drug & device makers
Across 391 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Novo Nordisk$576
- Otsuka America Pharmaceutical, Inc.$372
- Bayer$364
- Exact Sciences$337
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,818100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 73 | $1,193 |
| Boehringer Ingelheim | 64 | $1,067 |
| Novo Nordisk | 36 | $576 |
| Otsuka America Pharmaceutical, Inc. | 15 | $372 |
| Bayer | 19 | $364 |
| Exact Sciences | 13 | $337 |
| GSK | 20 | $321 |
| AbbVie(2 entities) | 15 | $287 |
| Ironwood Pharmaceuticals, Inc | 14 | $251 |
| Amgen(2 entities) | 14 | $246 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $241 |
| Pfizer | 19 | $208 |
| Shield Therapeutics Inc | 10 | $196 |
| Redhill Biopharma Inc. | 7 | $139 |
| Teva Pharmaceuticals USA, Inc. | 7 | $129 |
| Abbott | 4 | $88 |
| Novartis | 5 | $87 |
| Lilly USA, LLC | 5 | $84 |
| Biohaven Pharmaceuticals, Inc. | 5 | $79 |
| Johnson & Johnson | 5 | $67 |
| Eisai Inc. | 3 | $53 |
| Merck | 4 | $50 |
| Dexcom, Inc. | 3 | $50 |
| Lundbeck LLC | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Genentech USA, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Gilead | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Dermira, Inc. | 1 | $12 |
How this compares
$6,818 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnbrelEtanercept | 13 | $95,743 |
| OzempicSemaglutide | 88 | $94,431 |
| JardianceEmpagliflozin | 90 | $71,147 |
| EliquisApixaban | 89 | $69,315 |
| LinzessLinaclotide | 86 | $51,459 |
| FarxigaDapagliflozin Propanediol | 56 | $50,262 |
| JanuviaSitagliptin Phosphate | 53 | $40,928 |
| TrulicityDulaglutide | 36 | $34,919 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $26,731 |
| RexultiBrexpiprazole | 14 | $20,565 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $18,994 |
| KerendiaFinerenone | 22 | $18,028 |
| EntrestoSacubitril/Valsartan | 16 | $15,717 |
| MyrbetriqMirabegron | 22 | $13,935 |
| Lidocaine | 46 | $8,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $246 | $95,74313 claims |
| Novo NordiskOzempic | $576 | $94,43188 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,193 | $79,854106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,067 | $76,290101 claims |
| PfizerEliquis | $208 | $69,31589 claims |
| AbbVieLinzess | $287 | $51,45986 claims |
| MerckJanuvia, Janumet | $50 | $47,90966 claims |
| Lilly USA, LLCTrulicity | $84 | $34,91936 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $321 | $30,35660 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $372 | $20,56514 claims |
| BayerKerendia | $364 | $18,02822 claims |
| NovartisEntresto | $87 | $15,71716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Oak Park
- James VoigtOak Park$140K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.